Cited 12 time in
Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Naik, Ravi | - |
| dc.contributor.author | Han, Seunghyeon | - |
| dc.contributor.author | Lee, Kyeong | - |
| dc.date.accessioned | 2024-09-26T14:00:40Z | - |
| dc.date.available | 2024-09-26T14:00:40Z | - |
| dc.date.issued | 2015-09 | - |
| dc.identifier.issn | 0253-6269 | - |
| dc.identifier.issn | 1976-3786 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/25296 | - |
| dc.description.abstract | Intratumoral hypoxia has long been considered to be a driving force in tumor progression as well as a negative prognostic factor in human cancers. The discovery of hypoxia inducible factors (HIFs), which mediate transcriptional responses to changes in oxygen levels, has renewed enthusiasm for drug discovery and the development of targeted therapies in this field. LW6 represents an important new class of small molecules that inhibit HIF-1; it has been major source for diverse lead compounds including HIF-1 alpha inhibitors. Through a chemical biology approach, LW6-derived chemical probes were successfully utilized for the identification of the direct targeting of a protein in cancer. LW6 provides a valuable platform for the discovery and development of small molecule inhibitors of HIF-1 alpha-dependent tumor progression, metabolic reprogramming, and angiogenesis. | - |
| dc.format.extent | 12 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | PHARMACEUTICAL SOC KOREA | - |
| dc.title | Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1007/s12272-015-0632-5 | - |
| dc.identifier.scopusid | 2-s2.0-84942194613 | - |
| dc.identifier.wosid | 000361445000002 | - |
| dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.38, no.9, pp 1563 - 1574 | - |
| dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
| dc.citation.volume | 38 | - |
| dc.citation.number | 9 | - |
| dc.citation.startPage | 1563 | - |
| dc.citation.endPage | 1574 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART002029220 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
| dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
| dc.subject.keywordPlus | MALATE-DEHYDROGENASE | - |
| dc.subject.keywordPlus | SMALL-MOLECULE | - |
| dc.subject.keywordPlus | ACID ANALOGS | - |
| dc.subject.keywordPlus | FACTOR-I | - |
| dc.subject.keywordPlus | TARGET IDENTIFICATION | - |
| dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
| dc.subject.keywordPlus | DRUG-DISCOVERY | - |
| dc.subject.keywordPlus | MORACIN O | - |
| dc.subject.keywordPlus | HIF-1-ALPHA | - |
| dc.subject.keywordAuthor | HIF-1 alpha inhibitors | - |
| dc.subject.keywordAuthor | Chemical biology | - |
| dc.subject.keywordAuthor | Discovery | - |
| dc.subject.keywordAuthor | Angiogenesis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
